Erytech Pharma SA (ERYP):企業の財務・戦略的SWOT分析

GlobalDataが発行した調査報告書(DATA904C14970)
◆英語タイトル:Erytech Pharma SA (ERYP) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C14970
◆発行会社(リサーチ会社):GlobalData
◆発行日:2019年3月
◆ページ数:25
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD300 ⇒換算¥31,200見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD600 ⇒換算¥62,400見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥93,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Erytech Pharma SA (Erytech) is a clinical-stage biopharmaceutical company that provides development of therapies for rare forms of cancer and orphan diseases. The company develops pipeline of product candidates through its proprietary ERYCAPS platform. It offers product candidates which are intended for the treatment of acute myeloid leukemia, acute lymphoblastic leukemia, pancreatic cancer and non hodgkin lymphoma, among others. Erytech provides pipeline products such as eryasp, erymet, erymmune, and others. The company also develops other product candidates which uses encapsulated enzymes to induce tumor starvation. Its technology platform ERYCAPS uses red blood cells to discover therapeutic compounds. Erytech is headquartered in Lyon, France.

Erytech Pharma SA Key Recent Developments

Jan 18,2019: ERYTECH Presents TRYbeCA-1 Trial-in-Progress Poster at the 2019
Nov 15,2018: Erytech partners with New York Blood Center for red blood cell supply and research
Nov 14,2018: ERYTECH vermeldet die Ergebnisse des dritten Quartals 2018 und gibt ein Unternehmens-Update
Nov 12,2018: ERYTECH reports third quarter 2018 financial results and provides business update
Nov 07,2018: ERYTECH expands use of Medidata cloud to centrally manage all data for oncology trials

This comprehensive SWOT profile of Erytech Pharma SA provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Erytech Pharma SA including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Erytech Pharma SA – Key Information
Erytech Pharma SA – Overview
Erytech Pharma SA – Key Employees
Erytech Pharma SA – Key Employee Biographies
Erytech Pharma SA – Key Operational Heads
Erytech Pharma SA – Major Products and Services
Erytech Pharma SA – History
Erytech Pharma SA – Company Statement
Erytech Pharma SA – Locations And Subsidiaries
Erytech Pharma SA – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Erytech Pharma SA – Business Description
Erytech Pharma SA – Corporate Strategy
Erytech Pharma SA – SWOT Analysis
SWOT Analysis – Overview
Erytech Pharma SA – Strengths
Erytech Pharma SA – Weaknesses
Erytech Pharma SA – Opportunities
Erytech Pharma SA – Threats
Erytech Pharma SA – Key Competitors

Section 3 – Company Financial Performance Charts

Erytech Pharma SA – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Erytech Pharma SA, Key Information
Erytech Pharma SA, Key Ratios
Erytech Pharma SA, Share Data
Erytech Pharma SA, Major Products and Services
Erytech Pharma SA, History
Erytech Pharma SA, Key Employees
Erytech Pharma SA, Key Employee Biographies
Erytech Pharma SA, Key Operational Heads
Erytech Pharma SA, Other Locations
Erytech Pharma SA, Subsidiaries
Erytech Pharma SA, Key Manufacturing facilities
Erytech Pharma SA, Key Competitors
Erytech Pharma SA, SWOT Analysis
Erytech Pharma SA, Ratios based on current share price
Erytech Pharma SA, Annual Ratios
Erytech Pharma SA, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Erytech Pharma SA, Performance Chart
Erytech Pharma SA, Ratio Charts

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Erytech Pharma SA (ERYP):企業の財務・戦略的SWOT分析(Erytech Pharma SA (ERYP) - Financial and Strategic SWOT Analysis Review)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆